Shaji Kumar, MD
Hematology · Rochester, MNNPI 1568434090
Payments from drug & device makers
Across 911 payments — averaging $32,520 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$9M
- AbbVie$6.1M
- GSK$3.8M
- Amgen$2.6M
- Bristol Myers Squibb$2.5M
- Janssen Research & Development, LLC$2.3M
- plus $3.4M from 29 others
Across 55 payments — averaging $2965.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$112K
- Regeneron$16K
- F. Hoffmann-la Roche AG$14K
- Amgen$8K
- Pfizer$6K
- AbbVie$6K
- plus $1K from 1 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 172 | $8,984,421 |
| AbbVie | 181 | $6,074,554 |
| GSK | 68 | $3,755,948 |
| Amgen | 15 | $2,613,874 |
| Bristol Myers Squibb | 25 | $2,531,318 |
| Janssen Research & Development, LLC | 107 | $2,263,403 |
| Genentech, Inc. | 53 | $1,255,796 |
| AstraZeneca | 27 | $814,007 |
| Regeneron | 161 | $522,558 |
| Pfizer | 12 | $521,629 |
| Roche TCRC, Inc. | 1 | $75,000 |
| Eli Lilly | 2 | $38,650 |
| Gilead(2 entities) | 12 | $38,520 |
| Takeda | 3 | $24,883 |
| E.r. Squibb & Sons, L.L.C. | 9 | $22,577 |
| Janssen Global Services, LLC | 20 | $20,911 |
| Sanofi US Services Inc. | 1 | $16,614 |
| Sanofi | 5 | $9,326 |
| Janssen Scientific Affairs, LLC | 1 | $8,400 |
| Takeda Pharmaceutical Company, Limited | 1 | $6,400 |
| Celltrion, Inc. | 1 | $5,445 |
| F. Hoffmann-la Roche AG | 4 | $4,180 |
| Legend Biotech USA Inc. | 5 | $3,181 |
| Epizyme, Inc. | 1 | $2,700 |
| Beigene, Ltd. | 1 | $2,275 |
| Johnson & Johnson | 4 | $2,066 |
| BD | 1 | $2,000 |
| Biolinerx USA, Inc. | 1 | $1,563 |
| Dr.reddy's Laboratories,inc. | 1 | $1,500 |
| Taiho Oncology, Inc. | 10 | $762 |
| Novartis | 1 | $542 |
| The Binding Site Inc. | 1 | $300 |
| Merck | 2 | $239 |
| Secura Bio, Inc. | 1 | $200 |
| Beigene USA, Inc. | 1 | $26 |
How this compares
$29,625,766 in reported general payments places this provider in the 95th percentile of 111 hematology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology in Rochester
- Sameer ParikhRochester$44.6M
- Lindsey RoekerRochester$9.7M
- Yi LinRochester$9.2M
- Grzegorz NowakowskiRochester$9.1M
- Prashant KapoorRochester$7.6M
- Patrick JohnstonRochester$7.3M
- Mark LitzowRochester$7M
- Jose Villasboas BisnetoRochester$5.5M
- Stephen AnsellRochester$5.1M
- Angela DispenzieriRochester$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.